<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        6-5129-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        REOVAIR
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MONTELUKAST SODIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Chewable tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        60.00
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Alrai Pharmaceutical industry Co. (L.L.C)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Alrai Pharmaceutical industry Co. (L.L.C)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Alrai Pharmaceutical industry Co. (L.L.C)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R03DC03 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What REOVAIR Paediatric is</p><p>Reovair Paediatric contains the active substance Montelukast which belongs to a group of medicine called leukotriene receptor antagonist that blocks substance called leukotrienes.</p><p>How REOVAIR Paediatric works</p><p>Leukotrienes cause narrowing and swelling of airways in the lungs. By blocking leukotrienes, REOVAIR Paediatric improves asthma symptoms and helps control asthma.</p><p>When REOVAIR Paediatric should be used</p><p>Your doctor has prescribed REOVAIR Paediatric to treat asthma, preventing your asthma symptoms during the day and night.</p><p>&middot;&nbsp;REOVAIR Paediatric is used for the treatment of paediatric patients 6 to 14 years of age who are not adequately controlled on their medication and need additional therapy.</p><p>&middot; REOVAIR Paediatric may also be used as an alternative treatment to inhaled corticosteroids for 6 to14 year old patients who have not recently taken oral corticosteroids for their asthma and have shown that they are unable to use inhaled corticosteroids.</p><p>&middot; REOVAIR Paediatric also helps prevent the narrowing of airways triggered by exercise.</p><p>Your doctor will determine how REOVAIR Paediatric should be used depending on the symptoms and severity of you or your child&rsquo;s asthma.</p><p>What is asthma?</p><p>Asthma is a long-term disease.</p><p>Asthma includes:</p><p>&middot; Difficulty breathing because of narrowed airways. This narrowing of airways worsens and improves in response to various conditions.</p><p>&middot; Sensitive airways that react to many things, such as cigarette smoke, pollen, cold air, or exercise.</p><p>&middot;&nbsp; Swelling (inflammation) in the lining of the airways.</p><p>Symptoms of asthma include: Coughing, wheezing, and chest tightness.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tell your doctor about any medical problems or allergies you or your child has now or has had.</p><p>Do not take REOVAIR Paediatric</p><p>If you or your child is allergic to montelukast or any of the other ingredients of this medicine (listed in section 6).</p><p>Warnings and precautions&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Talk to your doctor or pharmacist before you or your child take REOVAIR Paediatric.</p><p>&middot; If you or your child&rsquo;s asthma or breathing gets worse, tell your doctor immediately.</p><p>&middot; Oral REOVAIR Paediatric is not meant to treat acute asthma attacks. If an attack occurs, follow the instructions your doctor has given you or your child. Always have your inhaled rescue medicine for asthma attacks with you.</p><p>&middot;&nbsp; It is important that you or your child take all asthma medications prescribed by your doctor.</p><p>&middot; Any patient on anti-asthma medicines should be aware that if you develop a combination of symptoms such as flu-like illness, pins and needles or numbness of arms or legs, worsening of pulmonary symptoms, and/or rash, you should consult your doctor.</p><p>&middot; You or your child should not take acetyl-salicylic acid (aspirin) or anti-inflammatory medicines (also known as non- steroidal anti-inflammatory drugs or NSAIDs) if they make your asthma worse.</p><p>Children and adolescents</p><p>Do not give this medicine to children less than 6 years of age.</p><p>Other medicines and REOVAIR Paediatric</p><p>Tell your doctor or pharmacist if you or your child are taking or have recently taken or might take any other medicines including those obtained without a prescription.</p><p>Some medicines may affect how REOVAIR Paediatric works, or REOVAIR Paediatric may affect how other medicines work.</p><p>Tell your doctor if you or your child is taking the following medicines before starting REOVAIR</p><p>Paediatric:</p><p>&middot; Phenobarbital (used for treatment of epilepsy)</p><p>&middot; Phenytoin (used for treatment of epilepsy)</p><p>&middot;&nbsp; Rifampicin (used to treat tuberculosis and some other infections)</p><p>REOVAIR Paediatric with food and drink</p><p>REOVAIR Paediatric 5 mg chewable tablets should not be taken immediately with food; it should be taken at least 1 hour before or two hours after food.</p><p>Pregnancy and Breast-feeding</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask&nbsp; your doctor or pharmacist for advice before taking REOVAIR Paediatric.</p><p>Pregnancy</p><p>Your doctor will assess whether you can take REOVAIR Paediatric during this time.</p><p>Breast-feeding</p><p>It is not known if REOVAIR Paediatric appears in breast milk. You should consult your doctor before taking REOVAIR Paediatric if you are breast-feeding or intend to breast-feed.</p><p>Driving and using machines</p><p>REOVAIR Paediatric is not expected to affect your ability to drive a car or operate machinery. However, individual responses to medication may vary. Certain side effects (such as dizziness and drowsiness) that have been reported with REOVAIR Paediatric may affect some patients&rsquo; ability to drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot; Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&middot; You or your child should take only one chewable tablet of REOVAIR Paediatric once a day as prescribed by your doctor.</p><p>&middot; It should be taken even when you or your child has no symptoms or has an acute asthma attack.</p><p>For children 6 to 14 years of age:</p><p>&middot; The recommended dose is one 5 mg chewable tablet daily to be taken in the evening.</p><p>&middot;&nbsp;If you or your child is taking REOVAIR Paediatric, be sure (that you or your child) does not take any other products that contain the same active ingredient, montelukast.</p><p>&middot;&nbsp;This medicine is for oral use.</p><p>&middot;&nbsp;The tablets are to be chewed before swallowing.</p><p>&middot;&nbsp;REOVAIR Paediatric 5 mg chewable tablets should not be taken immediately with food; it should be taken at least 1 hour before or two hours after food.</p><p>If you or your child takes more REOVAIR Paediatric than you should</p><p>Contact your doctor immediately for advice.</p><p>There were no side effects reported in the majority of overdosage reports. The most frequently occurring symptoms reported with overdosage in adults and children included abdominal pain, sleepiness, thirst, headache, vomiting, and hyperactivity.</p><p>If you forget to take REOVAIR Paediatric or give REOVAIR Paediatric to your child</p><p>Try to take REOVAIR Paediatric as prescribed. However, if you or your child misses a dose, just resume the usual schedule of one chewable tablet once daily.</p><p>Do not take a double dose to make up for a forgotten dose.</p><p>If you or your child stop taking REOVAIR Paediatric</p><p>REOVAIR Paediatric can treat you or your child&rsquo;s asthma only if you or your child continues to take it. It is important to continue taking REOVAIR Paediatric for as long as your doctor prescribes. It will help control you or your child&rsquo;s asthma.</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. In clinical studies with Montelukast Paediatric 5 mg chewable tablets, the most commonly reported side effects (may affect up to 1 in 10 people) thought to be related to Montelukast Paediatric were:</p><p>&middot; Headache</p><p>Additionally, the following side effect was reported in clinical studies with Montelukast 10 mg film coated tablets:</p><p>&middot; Abdominal pain</p><p>These were usually mild and occurred at a greater frequency in patients treated with Montelukast than placebo (a pill containing no medication).</p><p>Serious side effects</p><p><strong>Talk with your doctor immediately</strong> if you notice any of the following side effects, which may be serious, and for which you may need urgent medical treatment.</p><p>Uncommon: the following may affect up to 1 in 100 people</p><p>&middot; Allergic reactions including swelling of the face, lips, tongue, and/or throat which may cause difficulty in breathing or swallowing</p><p>&middot; Behavior and mood related changes: agitation including aggressive behavior or hostility, depression</p><p>&middot; Seizure</p><p>Rare: the following may affect up to 1 in 1,000 people</p><p>&middot;&nbsp;Increased bleeding tendency</p><p>&middot;&nbsp;Tremor</p><p>&middot; Palpitations</p><p>Very rare: the following may affect up to 1 in 10,000 people</p><p>&middot; Combination of symptoms such as flu-like illness, pins and needles or numbness of arms and legs, worsening of pulmonary symptoms and/or rash (Churg-Strauss syndrome) (see Section 2)</p><p>&middot;&nbsp;Low blood platelet count</p><p>&middot; Behavior and mood related changes: hallucinations, disorientation, suicidal thoughts and actions</p><p>&middot; Swelling (inflammation) of the lungs</p><p>&middot; Severe skin reactions (erythema multiforme) that may occur without warning</p><p>&middot; Inflammation of the liver (hepatitis)&nbsp; &nbsp; &nbsp; &nbsp;</p><p>Other side effects while the medicine has been on the market</p><p>Very common: the following may affect more than 1 in 10 people</p><p>&middot;&nbsp;Upper respiratory tract infection</p><p>Common: the following may affect up to 1 in 10 people</p><p>&middot; Diarrhea, nausea, vomiting</p><p>&middot; Rash</p><p>&middot; Fever</p><p>&middot; Elevated liver enzymes</p><p>Uncommon: the following may affect up to 1 in 100 people</p><p>&middot; Behavior and mood related changes: dream abnormalities, including nightmares, trouble sleeping, sleepwalking, irritability, feeling anxious, and restlessness</p><p>&middot; Dizziness, drowsiness, pins and needles/numbness</p><p>&middot; Nosebleed</p><p>&middot; Dry mouth, indigestion</p><p>&middot; Bruising, itching, hives</p><p>&middot; Joint or muscle pain, muscle cramps</p><p>&middot; Bedwetting in children</p><p>&middot;&nbsp;Weakness/tiredness, feeling unwell, swelling&nbsp; &nbsp; &nbsp;&nbsp;</p><p>Rare: the following may affect up to 1 in 1,000 people</p><p>&middot; Behavior and mood related changes: disturbance in attention, memory impairment, and uncontrolled muscle movements</p><p>Very rare: the following may affect up to 1 in 10,000 people</p><p>&middot; Tender red lumps under the skin, most commonly on your shins (erythema nodosum)</p><p>Reporting side effects:</p><p>If any of the side effects gets serious, or if you notice any possible side effects not listed in this leaflet, please tell your doctor or pharmacist. You can also report side effect directly (see section 6). By reporting side effect you can help provide more information on the safety of this medicine.</p><p><strong>To report any side effect(s):</strong></p><p><strong>Saudi Arabia:</strong></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>Fax: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; +966-11-205-7662</p><p>Call NPC at &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>Toll free phone: 8002490000</p><p>E-mail: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; npc.drug@sfda.gov.sa</p><p>Website: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; www.sfda.gov.sa/npc</p><p><strong>Other GCC States:</strong></p><p>Please contact the relevant competent authority</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot; Keep this medicine out of the sight and reach of children.</p><p>&middot; Do not use REOVAIR Paediatric after the expiry date which is stated on the carton and blister after &lsquo;EXP&rsquo;. The expiry date refers to the last day of that month.</p><p>&middot; Store in the original package in order to protect from light and moisture.</p><p>&middot;&nbsp;Do not Store above 30&deg;C</p><p>&middot; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What REOVAIR Paediatric 5 mg contains</p><p>&middot;The active substance is montelukast, REOVAIR Paediatric 5 mg chewable tablet contains montelukast sodium which corresponds to 5 mg of montelukast.</p><p>&middot;&nbsp;The other ingredients are: mannitol, microcrystalline cellulose, hydroxy propyl cellulose, red iron oxide, croscarmellose sodium, bubble gum flavor, colloidal silicon dioxide, and magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                •REOVAIR Paediatric 5 mg chewable tablets are pink, compact, biconvex, round tablet, embossed “A9” on one side. 
•REOVAIR Paediatric 5 mg is available in blister packs containing 28 tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Alrai Pharmaceutical Industries Co. (L.L.C.)</strong></p><p>Al Wadi - 2, Almu&rsquo;tasem Bellah Al Fatemy Street</p><p>P.O.Box:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9224 Jeddah - 21413 Kingdom of Saudi Arabia&nbsp;</p><p>Tel: +966 12 2888949</p><p>Fax:&nbsp;&nbsp;&nbsp; +966 12 2889014</p><p>E-mail:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; info@alraipharma.com</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 09/2019, Revision 0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو&nbsp; ريوڤـير&nbsp; للأطفال </strong></p><p dir="RTL">ريوڤير للأطفال يحتوي على المادة الفعالة مونيليوكاست التي تنتمي إلى مجموعة من الأدوية تسمى مضادات مستقبلات الليوكوترايين التي تمنع استقبال مواد تسمى الليوكوترايين.</p><p dir="RTL"><strong>كيف يعمل&nbsp; ريوڤـير&nbsp; للأطفال</strong></p><p dir="RTL">الليوكوتراينات تسبب ضيق وتورم مجرى التنفس في رئتيك. عن طريق حصر الليوكوترايين، فإن ريوڤير للأطفال يحسن أعراض الربو ويساعد على السيطرة على الربو.</p><p dir="RTL"><strong>متى يجب استخدام&nbsp; ريوڤـير&nbsp; للأطفال</strong></p><p dir="RTL">قد وصف لك طبيبك ريوڤير للأطفال لعلاج الربو، ومنع أعراض الربو خلال النهار والليل.</p><p dir="RTL">&middot;&nbsp; يستخدم ريوڤير للأطفال لعلاج الأطفال الذين تتراوح أعمارهم بين 6 و 14 سنة الذين لا يستجيبون بصورة كافية لأدوية الربو التي يستخدمونها ويحتاجون إلى علاج إضافي.</p><p dir="RTL">&middot; يمكن استخدام ريوڤير للأطفال كبديل للمستنشقات الكورتيكوستيرويدية لدى المرضى من عمر ٦ إلى ١٤ سنة في حالة عدم تناول مرضى الربو الأدوية الكورتيكوستيرويدية عن طريق الفم&nbsp; وعدم قدرتهم على استخدام المستنشقات الكورتيكوستيرويدية.</p><p dir="RTL">&middot;&nbsp;يساعد ريوڤير للأطفال أيضا على منع تضيق مجرى التنفس الذي يتهيج بأداء التمارين الرياضية.</p><p dir="RTL">سيقوم طبيبك بتحديد كيفية استخدام ريوڤير للأطفال اعتمادا على أعراض وشدة الربو لطفلك.</p><p dir="RTL"><strong>ما هو الربو؟</strong></p><p dir="RTL">الربو هو مرض رئوي مزمن.</p><p dir="RTL">ويشمل الربو ما يلي:</p><p dir="RTL">&middot;&nbsp; صعوبة التنفس بسبب ضيق في مجرى التنفس. وهذا الضيق يزداد سوءًا أو يتحسن تبعًا لتغير الظروف.</p><p dir="RTL">&middot;&nbsp; يتأثر مجرى التنفس بالعديد من المؤثرات، مثل دخان السجائر، حبوب اللقاح، برودة الجو أو التمارين العضلية.</p><p dir="RTL">&middot; تورم (التهاب) بطانة مجرى التنفس.</p><p dir="RTL">وتشمل أعراض الربو ما يلي: السعال، صفير عند التنفس وضيق في الصدر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">اخبر طبيبك إذا كنت تعاني أنت أو طفلك من مشاكل طبية أو حساسية مصابون بها الآن أو أصبتم بها مسبقاً.</p><p dir="RTL"><strong>لا تتناول&nbsp; ريوڤـير&nbsp; للأطفال</strong></p><p dir="RTL">إذا كنت تعاني من الحساسية لمونتيلوكاست أنت أو طفلك أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6).</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل أن تتناول أنت أو طفلك لـ ريوڤير للأطفال.</p><p dir="RTL">&middot;&nbsp;إذا تدهورت حالة الربو أو التنفس لديك أو لدى طفلك فأخبر طبيبك على الفور.</p><p dir="RTL">&middot;&nbsp;لا يقصد ب ريوڤير للأطفال الفموي كعلاج لنوبات الربو المفاجئة، إذا حدثت النوبة، اتبع تعليمات الطبيب التي ذكرها لك بخصوصك أو بخصوص طفلك، ومن المهم أن يكون دواء الإستنشاق لإنقاذ نوبة الربو&nbsp; جاهزًا معك.</p><p dir="RTL">&middot;&nbsp;من المهم أن تتناول أنت أو طفلك جميع أدوية الربو التي وصفها الطبيب حسب الحاجة، ولا يجب الاستعاضة بـ ريوڤير للأطفال عن أدوية الربو الأخرى التي وصفها الطبيب.</p><p dir="RTL">&middot; أي مريض يتناول أدوية الربو يجب أن ينتبه ويخبر طبيبه عند حدوث مجموعة من الأعراض مثل أعراض شبيهة بالأنفلونزا، الشعور بوخز وتنميل أو خدر في الذراعين والساقين، تدهور الأعراض الصدرية، و /أو طفح جلدي.</p><p dir="RTL">&middot; يجب أن لا تتناول أنت أو طفلك الأسيتيل ساليسيليك أسيد (الأسبرين) أو الأدوية الأخرى الغير ستيرويدية المضادة للإلتهاب (والتي تعرف أيضاً بمضادات الالتهاب الغير ستيرويدية أو NSAIDs إذا أدت إلى تدهور حالة الربو لديك / أو لدى طفلك.</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">لا يعطى هذا الدواء للأطفال الذين تقل أعمارهم عن 6 سنوات.</p><p dir="RTL"><strong>ريوڤـير&nbsp; للأطفال والأدوية الأخرى </strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت أنت أو طفلك تناولت أو اخذت مؤخرا أو قد تتناول أي من الأدوية التي تحصل عليها دون وصفة طبية.</p><p dir="RTL">بعض الأدوية قد تؤثر على كيفية عمل ريوڤير للأطفال، أو ريوڤير للأطفال قد يؤثر على كيفية عمل الأدوية الأخرى.</p><p dir="RTL">أخبر طبيبك إذا كنت تتناول أنت أو طفلك الأدوية التالية قبل البدء بتناول ريوڤير للأطفال:</p><p dir="RTL">&middot; فينوباربيتال (يستخدم لعلاج الصرع).</p><p dir="RTL">&middot;&nbsp; فينيتوين (يستخدم لعلاج الصرع).</p><p dir="RTL">&middot;&nbsp; ريفامبيسين (يستخدم لعلاج السل وبعض الإلتهابات الأخرى).</p><p dir="RTL"><strong>ريوڤـير&nbsp; للأطفال مع الطعام والشراب</strong></p><p dir="RTL">يجب عدم تناول أقراص ريوڤير للأطفال 5 ملجم للمضغ مع الطعام، يجب أن يتم تناوله إما ساعة قبل الأكل أو ساعتين بعده.</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">إذا كنتِ حاملاً أو ترضعين رضاعة طبيعية أو تعتقدين أنك قد تكونين حاملاً فاستشيري الطبيب أو الصيدلي قبل استخدام هذا الدواء.</p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">سيقوم طبيبك بتقييم ما إذا كان يمكنك أخذ ريوڤير للأطفال خلال هذه الفترة.</p><p dir="RTL"><strong>الرضاعة </strong></p><p dir="RTL">لا يعرف ما إذا كان ريوڤير للأطفال يفرز في حليب الأم أم لا. ويجب استشارة الطبيب قبل تناول&nbsp; ريوڤير للأطفال وذلك إذا كنت مرضعة أو تنوين إرضاع طفلك.</p><p dir="RTL"><strong>القيادة واستعمال الآلات</strong></p><p dir="RTL">لا يتوقع أن يؤثر ريوڤير للأطفال في قدرتك على قيادة السيارات وتشغيل الآلات، وعلى كل حال، فقد تختلف الاستجابة للدواء من شخص لآخر، وبعض الآثار الجانبية (مثل الدوار والدوخة) والتي سجلت مع ريوڤير للأطفال قد تؤثر على قدرة المريض على قيادة السيارات أو تشغيل الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول دائمًا الدواء تمامًا كما قال لك الطبيب أو الصيدلي. تحقق مع طبيبك أو الصيدلي إذا لم تكن متأكدًا.</p><p dir="RTL">يجب أن تتناول أنت أو طفلك&nbsp; أقراص ريوڤير 5 ملجم للمضغ مرة يومياً حسب تعليمات الطبيب.</p><p dir="RTL">يجب أن يتم تناوله ايضاً حتى في حالة اختفاء الأعراض أو نوبات الربو المفاجئة&nbsp; لديك أو لدى طفلك.</p><p dir="RTL"><strong>بالنسبة للأطفال الذين تتراوح أعمارهم من ٦ إلى ١٤ سنة:</strong></p><p dir="RTL">الجرعة الموصى بها هي 5 ملجم قرص مضغ يوميا ليتم تناوله في المساء.</p><p dir="RTL">إذاكنت تتناول أنت أو طفلك ريوڤير للأطفال، تأكد من (أنك أو طفلك) لا تتناول منتج آخر يحتوي على نفس المادة الفعالة، مونتيليوكاست.</p><p dir="RTL">هذا الدواء للاستخدام عن طريق الفم.</p><p dir="RTL">يجب مضغ الأقراص قبل البلع.</p><p dir="RTL">يجب تناول قرص واحد للمضغ من ريوڤير للأطفال 5 ملجم يومياً في المساء، يجب تناولها إما قبل الطعام بساعة أو بعده بساعتين.</p><p dir="RTL"><strong>إذا تناولت أنت أو طفلك أكثر من ما يجب من&nbsp; ريوڤـير&nbsp; للأطفال </strong></p><p dir="RTL">اتصل بطبيبك فوراً طلباً للمساعدة.</p><p dir="RTL">لم تسجل أي آثار جانبية مع معظم تقارير تجاوز الجرعة، وأكثر الآثار الجانبية التي تم تسجيل وقوعها مع تجاوز الجرعة في الكبار شملت ألم البطن، نعاس، عطش، صداع، تقيؤ، وفرط النشاط.</p><p dir="RTL"><strong>إذا كنت قد نسيت أن تتناول&nbsp; ريوڤـير&nbsp; للأطفال أو إعطاء&nbsp; ريوڤـير&nbsp; للأطفال لطفلك</strong></p><p dir="RTL">حاول أن تعطي ريوڤير للأطفال كما هو موصوف. وعلى العموم، إذا نسيت تناول أو إعطاء طفلك الجرعة تابع الجدول الاعتيادي للجرعة وهو قرص مضغ مرة واحدة يومياً. لا تعطي جرعة إضافية لتعوض ما نقص.</p><p dir="RTL"><strong>إذا توقفت أنت أو طفلك عن تناول&nbsp; ريوڤـير&nbsp; للأطفال:</strong></p><p dir="RTL">يمكن أن يعالج ريوڤير للأطفال مرض الربو لديك أو لدى طفلك فقط إذا تم الالتزام على تناوله. من المهم الإستمرار بتناول ريوڤير للأطفال طوال الفترة التي وصفها الطبيب ليساعد في السيطرة على مرض الربو لديك أو لدى طفلك.</p><p dir="RTL">إذا كان لديك مزيد من الاستفسارا ت عن استخدام هذا المستحضر، استشر الطبيب أو الصيدلاني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع جميع الأدوية، فإن هذا الدواء قد يسبب آثاراً جانبية، إلا أنها قد لا تحدث مع جميع المرضى.</p><p dir="RTL">وفي الدراسات السريرية التي أجريت على أقراص مونتيليوكاست للأطفال 5 ملجم للمضغ، كانت الآثار الجانبية الأكثر شيوعًا (قد تؤثر على ما يصل إلى 1 من كل 10 أشخاص) ويعتقد أنها مرتبطة بـالمونتيليوكاست للأطفال:</p><p dir="RTL">&middot; صداع.</p><p dir="RTL">بالإضافة إلى ذلك، تم الإبلاغ عن الآثار الجانبية التالية في الدراسات السريرية مع أقراص مونتيليوكاست 10 ملجم المغلفة غشائياً:</p><p dir="RTL">&middot; آلام البطن</p><p dir="RTL">وقد كانت هذه الآثار بسيطة وحدثت بغالبية أكبر في المرضى الذين أعطوا مونيليوكاست مقارنة بالذين أعطو العلاج الوهمي (القرص الذي لا يحتوي على دواء).</p><p dir="RTL"><strong>آثار جانبية خطيرة</strong></p><p dir="RTL">تحدث مع طبيبك على الفور إذا لاحظت أيًا من الآثار الجانبية التالية، والتي قد تكون خطيرة، وقد تحتاج إلى علاج طبي عاجل.</p><p dir="RTL"><strong>غير شائع: قد يؤثر ما يلي على ما يصل إلى شخص واحد من بين كل ١٠٠ شخص</strong></p><p dir="RTL">&middot;الحساسية، بما في ذلك تورم الوجه والشفتين واللسان و / أو الحلق مما قد يسبب صعوبة في التنفس أو البلع.</p><p dir="RTL">&middot; تغيير بالسلوك والمزاج: هيجان بما في ذلك السلوك الفظ أو العدوانية والاكتئاب</p><p dir="RTL">&middot; تشنج</p><p dir="RTL"><strong>نادر: قد يؤثر ما يلي على ما يصل إلى شخص من كل ١٠٠٠ شخص</strong></p><p dir="RTL">&middot; زيادة القابلية للنزيف</p><p dir="RTL">&middot; رعشة</p><p dir="RTL">&middot;&nbsp; خفقان</p><p dir="RTL"><strong>نادر جدًا: قد يؤثر ما يلي على ما يصل إلى شخص من كل ١٠٠٠٠ شخص</strong></p><p dir="RTL">&middot;&nbsp; مزيج من الأعراض مثل أعراض شبيهة بالأنفلونزا، وخزات وتنميل أو خدر في الذراعين والساقين، وتفاقم الأعراض الرئوية و / أو الطفح الجلدي (متلازمة تشيرج ستراوس) (انظر القسم 2)</p><p dir="RTL">&middot;&nbsp; انخفاض عدد الصفائح الدموية في الدم</p><p dir="RTL">&middot; التغييرات المرتبطة بالسلوك والمزاج: الهلوسة، الارتباك، والأفكار الانتحارية</p><p dir="RTL">&middot; تورم (التهاب) الرئتين</p><p dir="RTL">&middot;&nbsp;ردود الفعل الجلدية الشديدة (حمامي متعددة الأشكال) التي قد تحدث دون سابق إنذار</p><p dir="RTL">&middot; التهاب الكبد</p><p dir="RTL"><strong>وإضافة لذلك، أثناء تسويق الدواء تم تسجيل الآثار الجانبية التالية:</strong></p><p dir="RTL"><strong>شائع جدًا: قد يؤثر ما يلي على أكثر من شخص من كل ١٠ أشخاص</strong></p><p dir="RTL">&middot; عدوى الجهاز التنفسي العلوي</p><p dir="RTL"><strong>شائع: قد يؤثر ما يلي على ما يصل إلى شخص من كل ١٠ أشخاص</strong></p><p dir="RTL">&middot; الإسهال والغثيان والقيء</p><p dir="RTL">&middot; طفح جلدي</p><p dir="RTL">&middot; حمى</p><p dir="RTL">&middot; ارتفاع إنزيمات الكبد</p><p dir="RTL"><strong>غير شائع: قد يؤثر ما يلي على ما يصل إلى شخص واحد من بين كل </strong>١<strong>٠٠ شخص</strong></p><p dir="RTL">&middot; التغيرات المرتبطة بالسلوك والمزاج: اضطراب الأحلام، بما في ذلك الكوابيس، مشاكل النوم، والسير أثناء النوم، والتهيج، والشعور بالقلق</p><p dir="RTL">&middot;&nbsp; الدوخة والنعاس، الإحساس بوخز خفيف وتنميل</p><p dir="RTL">&middot;&nbsp; نزيف في الأنف</p><p dir="RTL">&middot; جفاف الفم وعسر الهضم</p><p dir="RTL">&middot;كدمات، حكة</p><p dir="RTL">&middot;آلام المفاصل أو العضلات، تشنجات العضلات</p><p dir="RTL">&middot; التبول اللاإرادي عند الأطفال</p><p dir="RTL">&middot; الضعف / التعب، والشعور بالإعياء، والتورم</p><p dir="RTL"><strong>نادر: قد يؤثر ما يلي على ما يصل إلى شخص من كل ١٠٠٠ شخص</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;تغيير بالسلوك والمزاج: اضطراب في الانتباه، وضعف الذاكرة، وتشنجات بالعضلات.</p><p dir="RTL"><strong>نادر جدًا: قد يؤثر ما يلي على ما يصل إلى شخص من كل ١٠٠٠٠ شخص</strong></p><p dir="RTL">&middot;&nbsp; بروز كتل حمراء تحت الجلد وعادة ما تكون في السيقان (الحمامى العقدية)</p><p dir="RTL"><strong>الإبلاغ</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>الأعراض</strong><strong> </strong><strong>الجانبية</strong><strong>:</strong></p><p dir="RTL"><strong>&bull;</strong><strong>المملكة</strong><strong> </strong><strong>العربية</strong><strong> </strong><strong>السعودية:</strong></p><p dir="RTL">المركز الوطني للتيقظ والسلامة الدوائية</p><p dir="RTL">فاكس: 7662-205-11-966+&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</p><p dir="RTL">للاتصال بالإدارة التنفيذية للتيقظ وإدارة الأزمات:</p><p dir="RTL">هاتف: 2038222-11-966+&nbsp; &nbsp;تحويلة: 2317-2356-2353-2354-2334-2340</p><p dir="RTL">الهاتف المجاني:&nbsp;&nbsp; &nbsp;8002490000</p><p dir="RTL">البريد الإلكتروني:&nbsp;&nbsp; &nbsp;npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: www.sfda.gov.sa/npc&nbsp;&nbsp;</p><p dir="RTL"><strong>&bull;</strong><strong>دول</strong><strong> </strong><strong>الخليج</strong><strong> </strong><strong>الأخرى</strong><strong>:</strong></p><p dir="RTL">الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف يتم تخزين&nbsp; ريوڤـير للاطفال</strong></p><p dir="RTL">&middot; احفظها بعيداً عن متناول الأطفال.</p><p dir="RTL">&middot;&nbsp;لا تتناول ريوڤير للأطفال بعد تاريخ الانتهاء الموضح بعد كلمة (EXP) على العبوة والكرتون. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</p><p dir="RTL">&middot;&nbsp;احفظه في العبوة الأًصلية لتحميه من الضوء والرطوبة.</p><p dir="RTL">&middot;&nbsp; لا يحفظ في درجة حرارة أكثر من ٣٠&deg;م.</p><p>يجب عدم التخلص من الأدوية في مياه الصرف الصحي أو مع مخلفات المنزل، اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجتها، لأن هذه الإجراءات ستساعد على حماية البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هي محتويات&nbsp; ريوڤـير&nbsp; للأطفال ٥ ملجم:</strong></p><p dir="RTL">&middot; المادة الفعالة: مونتيليوكاست. اقراص ريوڤير للأطفال 5 ملجم للمضغ تحتوي على مونتيليوكاست الصوديوم والذي يعادل 5 ملجم من مونتيليوكاست.</p><p dir="RTL">&middot; مكونات أخرى:&nbsp; مانيتول، سيليوليوز دقيق البلورات ، هيدروكسي بروبيل السليلوز، أكسيد الحديد الأحمر، كروسكارميلوز الصوديوم، نكهة العلكة، ثاني أكسيد السيليكون الغروية، ستيرات المغنيسيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot; ريوڤير للأطفال 5 ملجم أقراص للمضغ وردية اللون، مضغوطة، محدبة الوجهين، قرص مستدير،منقوش على أحد جانبي القرص (A9).</p><p dir="RTL">&middot; ريوڤير للأطفال 5 ملجم متوفر في ظروف تحتوي على 28 قرص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة</strong><strong> </strong><strong>الصانعة</strong><strong> </strong><strong>والمالكة</strong><strong> </strong><strong>لحق</strong><strong> </strong><strong>التسويق</strong></p><p dir="RTL"><strong>شركة مصنع الرأي للصناعات الدوائية (ذ.م.م.)</strong></p><p dir="RTL">الوادي- 2، شارع المعتصم بالله الفاطمي</p><p dir="RTL">صندوق بريد: 9224 جدة - ٢١٤١٣ المملكة العربية السعودية</p><p dir="RTL">تلفون:&nbsp; &nbsp; 966122888949+&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p><p dir="RTL">فاكس:&nbsp; &nbsp;966122889014+&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</p><p dir="RTL">ايميل:&nbsp; Info@alraipharma.com&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم اعتماد هذه النشرة في ٩/٢٠١٩، نسخة رقم (٠)
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Reovair Paediatric 5 mg chewable Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One chewable tablet contains montelukast sodium, which is equivalent to 5 mg montelukast.
 For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Chewable tablet.

Pink, compact, biconvex, round, 9.5 mm embossed “A9” uncoated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reovair is indicated in the treatment of asthma as add-on therapy in those patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom &ldquo;as-needed&rdquo; short-acting &beta;-agonists provide inadequate clinical control of asthma.</p><p>Reovair may also be an alternative treatment option to low-dose inhaled corticosteroids for patients with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids (see section 4.2).</p><p>Reovair is also indicated in the prophylaxis of asthma in which the predominant component is exercise- induced bronchoconstriction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>The recommended dose for paediatric patients 6-14 years of age is one 5 mg chewable tablet daily to be taken in the evening. If taken in connection with food, Reovair should be taken 1 hour before or 2 hours after food. No dosage adjustment within this age group is necessary.</p><p><u>General recommendations</u></p><p>The therapeutic effect of Reovair on parameters of asthma control occurs within one day. Patients should be advised to continue taking Reovair even if their asthma is under control, as well as during periods of worsening asthma.</p><p>No dosage adjustment is necessary for patients with renal insufficiency, or mild to moderate hepatic impairment. There are no data on patients with severe hepatic impairment. The dosage is the same for both male and female patients.</p><p><u>Reovair as an alternative treatment option to low-dose inhaled corticosteroids for mild persistent asthma</u></p><p>Montelukast is not recommended as monotherapy in patients with moderate persistent asthma. The use of montelukast as an alternative treatment option to low-dose inhaled corticosteroids for children with mild persistent asthma should only be considered for patients who do not have a recent history of serious asthma attacks that required oral corticosteroid use and who have demonstrated that they are not capable of using inhaled corticosteroids (see section 4.1). Mild persistent asthma is defined as asthma symptoms more than once a week but less than once a day, nocturnal symptoms more than twice a month but less than once a week, normal lung function between episodes. If satisfactory control of asthma is not achieved at follow-up (usually within one month), the need for an additional or different anti- inflammatory therapy based on the step system for asthma therapy should be evaluated. Patients should be periodically evaluated for their asthma control.</p><p><u>Therapy with Reovair in relation to other treatments for asthma</u></p><p>When treatment with Reovair is used as add-on therapy to inhaled corticosteroids, Reovair should not be abruptly substituted for inhaled corticosteroids (see section 4.4).</p><p>10 mg tablets are available for adults and adolescents 15 years of age and older.</p><p><em>Paediatric population</em></p><p>Do not give Reovair 5 mg chewable tablets to children less than 6 years of age. The safety and efficacy of Reovair 5 mg chewable tablets in children less than 6 years of age has not been established.</p><p>4 mg chewable tablets are available for paediatric patients 2 to 5 years of age. 4 mg granules are available for paediatric patients 6 months to 5 years of age.<u> </u></p><p><u>Method of administration</u></p><p>Oral use.</p><p>The tablets are to be chewed before swallowing.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should be advised never to use oral montelukast to treat acute asthma attacks and to keep their usual appropriate rescue medication for this purpose readily available. If an acute attack occurs, a short- acting inhaled &beta;-agonist should be used. Patients should seek their doctors&#39; advice as soon as possible if they need more inhalations of short-acting &beta;-agonists than usual.</p><p>Montelukast should not be abruptly substituted for inhaled or oral corticosteroids.</p><p>There are no data demonstrating that oral corticosteroids can be reduced when montelukast is given concomitantly.</p><p>In rare cases, patients on therapy with anti-asthma agents including montelukast may present with systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg- Strauss syndrome, a condition which is often treated with systemic corticosteroid therapy. These cases have been sometimes associated with the reduction or withdrawal of oral corticosteroid therapy. Although a causal relationship with leukotriene receptor antagonism has not been established, physicians should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. Patients who develop these symptoms should be reassessed and their treatment regimens evaluated.</p><p>Treatment with montelukast does not alter the need for patients with aspirin-sensitive asthma to avoid taking aspirin and other non-steroidal anti-inflammatory drugs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Montelukast may be administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma. In drug-interactions studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following medicinal products: theophylline, prednisone, prednisolone, oral contraceptives (ethinyl oestradiol/norethindrone 35/1), terfenadine, digoxin and warfarin.</p><p>The area under the plasma concentration curve (AUC) for montelukast was decreased approximately 40% in subjects with co-administration of phenobarbital. Since montelukast is metabolised by CYP 3A4, 2C8, and 2C9, caution should be exercised, particularly in children, when montelukast is co-administered with inducers of CYP 3A4, 2C8, and 2C9, such as phenytoin, phenobarbital and rifampicin.</p><p><em>In vitro </em>studies have shown that montelukast is a potent inhibitor of CYP 2C8. However, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of medicinal products primarily metabolised by CYP 2C8) demonstrated that montelukast does not inhibit CYP 2C8 <em>in vivo. </em>Therefore, montelukast is not anticipated to markedly alter the metabolism of medicinal products metabolised by this enzyme (e.g., paclitaxel, rosiglitazone, and repaglinide).</p><p><em>In vitro </em>studies have shown that montelukast is a substrate of CYP 2C8, and to a less significant extent, of 2C9, and 3A4. In a clinical drug-drug interaction study involving montelukast and gemfibrozil (an inhibitor of both CYP 2C8 and 2C9) gemfibrozil increased the systemic exposure of montelukast by 4.4- fold. No routine dosage adjustment of montelukast is required upon co-administration with gemfibrozil or other potent inhibitors of CYP 2C8, but the physician should be aware of the potential for an increase in adverse reactions.</p><p>Based on <em>in vitro </em>data, clinically important drug interactions with less potent inhibitors of CYP 2C8 (e.g., trimethoprim) are not anticipated. Co-administration of montelukast with itraconazole, a strong inhibitor of CYP 3A4, resulted in no significant increase in the systemic exposure of montelukast.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Animal studies do not indicate harmful effects with respect to effects on pregnancy or embryonal/foetal development.</p><p>Limited data from available pregnancy databases do not suggest a causal relationship between montelukast and malformations (i.e. limb defects) that have been rarely reported in worldwide post- marketing experience.</p><p>Reovair may be used during pregnancy only if it is considered to be clearly essential.</p><p><u>Breast-feeding</u></p><p>Studies in rats have shown that montelukast is excreted in milk (see section 5.3). It is unknown whether montelukast/metabolites are excreted in human milk.</p><p>Reovair may be used in breast-feeding mothers only if it is considered to be clearly essential.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reovair has no or negligible influence on the ability to drive and use machines. However, individuals have reported drowsiness or dizziness.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Montelukast has been evaluated in clinical studies as follows:</p><p>&bull;&nbsp; 10 mg film-coated tablets in approximately 4,000 adult and adolescent patients 15 years of age and older, and</p><p>&bull;&nbsp; 5 mg chewable tablets in approximately 1,750 paediatric patients 6 to 14 years of age.</p><p>The following drug-related adverse reactions in clinical studies were reported commonly (&ge;1/100 to</p><p>&lt;1/10) in patients treated with montelukast and at a greater incidence than in patients treated with placebo:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:165px"><p><strong>Body System Class</strong></p></td><td style="vertical-align:top; width:248px"><p><strong>Adult and Adolescent Patients 15 years and older (two 12-week studies; n=795)</strong></p></td><td style="vertical-align:top; width:318px"><p><strong>Paediatric Patients 6 to 14 years old</strong></p><p><strong>(one 8-week study; n=201)</strong></p><p><strong>(two 56-week studies; n=615)</strong></p></td></tr><tr><td style="vertical-align:top; width:165px"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top; width:248px"><p>headache</p></td><td style="vertical-align:top; width:318px"><p>headache</p></td></tr><tr><td style="vertical-align:top; width:165px"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top; width:248px"><p>abdominal pain</p></td><td style="vertical-align:top; width:318px"><p>&nbsp;</p></td></tr></tbody></table><p>With prolonged treatment in clinical trials with a limited number of patients for up to 2 years for adults, and up to 12 months for paediatric patients 6 to 14 years of age, the safety profile did not change.</p><p><u>Tabulated list of Adverse Reactions</u></p><p>Adverse reactions reported in post-marketing use are listed, by System Organ Class and specific Adverse Reactions, in the table below. Frequency Categories were estimated based on relevant clinical trials.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:173px"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top; width:472px"><p><strong>Adverse Reactions</strong></p></td><td style="vertical-align:top"><p><strong>Frequency Category*</strong></p></td></tr><tr><td style="vertical-align:top; width:173px"><p>Infections and infestations</p></td><td style="vertical-align:top; width:472px"><p>upper respiratory infection<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top; width:173px"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top; width:472px"><p>increased bleeding tendency</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:173px"><p>Immune system disorders</p></td><td style="vertical-align:top; width:472px"><p>hypersensitivity reactions including anaphylaxis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top; width:472px"><p>hepatic eosinophilic infiltration</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td rowspan="3" style="vertical-align:top; width:173px"><p>Psychiatric disorders</p></td><td style="vertical-align:top; width:472px"><p>dream abnormalities including nightmares, insomnia, somnambulism, anxiety, agitation including aggressive behaviour or hostility, depression, psychomotor hyperactivity (including irritability, restlessness, tremor<sup>&sect;</sup>)</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top; width:472px"><p>disturbance in attention, memory impairment</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top; width:472px"><p>hallucinations, disorientation, suicidal thinking and behaviour (suicidality)</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:173px"><p>Nervous system disorders</p></td><td style="vertical-align:top; width:472px"><p>dizziness, drowsiness, paraesthesia/hypoesthesia, seizure</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top; width:173px"><p>Cardiac disorders</p></td><td style="vertical-align:top; width:472px"><p>palpitations</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="3" style="vertical-align:top; width:173px"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top; width:472px"><p>epistaxis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top; width:472px"><p>Churg-Strauss Syndrome (CSS) (see section 4.4)</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td style="vertical-align:top; width:472px"><p>pulmonary eosinophilia</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:173px"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top; width:472px"><p>diarrhoea&Dagger;, nausea&Dagger;, vomiting&Dagger;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:472px"><p>dry mouth, dyspepsia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:173px"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top; width:472px"><p>elevated levels of serum transaminases (ALT, AST)</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:472px"><p>hepatitis (including cholestatic, hepatocellular, and mixed-pattern liver injury)</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td rowspan="4" style="vertical-align:top; width:173px"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top; width:472px"><p>rash&Dagger;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:472px"><p>bruising, urticaria, pruritus</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top; width:472px"><p>angiooedema</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top; width:472px"><p>erythema nodosum, erythema multiforme</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td style="vertical-align:top; width:173px"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top; width:472px"><p>arthralgia, myalgia including muscle cramps</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:173px"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top; width:472px"><p>pyrexia&Dagger;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:472px"><p>asthenia/fatigue, malaise, oedema</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*Frequency Category: Defined for each Adverse Reaction by the incidence reported in the clinical trials data base: Very Common (&ge;1/10), Common (&ge;1/100 to &lt;1/10), Uncommon (&ge;1/1,000 to &lt;1/100), Rare (&ge;1/10,000 to</p><p>&lt;1/1,000), Very Rare (&lt;1/10,000).</p><p>&dagger;This adverse experience, reported as Very Common in the patients who received montelukast, was also reported as Very Common in the patients who received placebo in clinical trials.</p><p>&Dagger;This adverse experience, reported as Common in the patients who received montelukast, was also reported as Common in the patients who received placebo in clinical trials.</p><p>&sect; Frequency Category: Rare</p></td></tr></tbody></table><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p><strong>To report any side effect(s): Saudi Arabia:</strong></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o&nbsp; Toll free phone: 8002490000</p><p>o&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp; Website: www.sfda.gov.sa/npc</p><p><u>Other GCC States:</u></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In chronic asthma studies, montelukast has been administered at doses up to 200 mg/day to adult patients for 22 weeks and in short-term studies, up to 900 mg/day to patients for approximately one week without clinically important adverse experiences.</p><p>There have been reports of acute overdose in post-marketing experience and clinical studies with montelukast. These include reports in adults and children with a dose as high as 1,000 mg (approximately 61 mg/kg in a 42 month old child). The clinical and laboratory findings observed were consistent with the safety profile in adults and paediatric patients. There were no adverse experiences in the majority of overdose reports.</p><p><u>Symptoms of overdose</u></p><p>The most frequently occurring adverse experiences were consistent with the safety profile of montelukast and included abdominal pain, somnolence, thirst, headache, vomiting, and psychomotor hyperactivity.</p><p><u>Management of overdose</u></p><p>No specific information is available on the treatment of overdose with montelukast. It is not known whether montelukast is dialysable by peritoneal- or haemo-dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Leukotriene receptor antagonist</p><p>ATC-Code: R03D C03</p><p><u>Mechanism of action</u></p><p>The cysteinyl leukotrienes (LTC<sub>4</sub>, LTD<sub>4</sub>, LTE<sub>4</sub>) are potent inflammatory eicosanoids released from various cells including mast cells and eosinophils. These important pro-asthmatic mediators bind to cysteinyl leukotriene receptors (CysLT) found in the human airway and cause airway actions, including bronchoconstriction, mucous secretion, vascular permeability, and eosinophil recruitment.</p><p><u>Pharmacodynamic effects</u></p><p>Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT<sub>1</sub> receptor. In clinical studies, montelukast inhibits bronchoconstriction due to inhaled LTD<sub>4</sub> at doses as low as 5 mg. Bronchodilation was observed within two hours of oral administration. The</p><p>bronchodilation effect caused by a &beta;-agonist was additive to that caused by montelukast. Treatment with montelukast inhibited both early- and late-phase bronchoconstriction due to antigen challenge.</p><p>Montelukast, compared with placebo, decreased peripheral blood eosinophils in adult and paediatric patients. In a separate study, treatment with montelukast significantly decreased eosinophils in the airways (as measured in sputum) and in peripheral blood while improving clinical asthma control.</p><p><u>Clinical efficacy and safety</u></p><p>In studies in adults, montelukast, 10 mg once daily, compared with placebo, demonstrated significant improvements in morning FEV<sub>1</sub> (10.4% vs 2.7% change from baseline), AM peak expiratory flow rate (PEFR) (24.5 L/min vs 3.3 L/min change from baseline), and significant decrease in total &beta;-agonist use (- 26.1% vs -4.6% change from baseline). Improvement in patient-reported daytime and night-time asthma symptoms scores was significantly better than placebo.</p><p>Studies in adults demonstrated the ability of montelukast to add to the clinical effect of inhaled corticosteroid (% change from baseline for inhaled beclomethasone plus montelukast vs beclomethasone, respectively for FEV<sub>1</sub> : 5.43% vs 1.04%; &beta;-agonist use: -8.70% vs 2.64%). Compared with inhaled beclomethasone (200 &mu;g twice daily with a spacer device), montelukast demonstrated a more rapid initial response, although over the 12-week study, beclomethasone provided a greater average treatment effect (% change from baseline for montelukast vs beclomethasone, respectively for FEV<sub>1</sub> : 7.49% vs 13.3%; &beta;- agonist use: -28.28% vs -43.89%). However, compared with beclomethasone, a high percentage of patients treated with montelukast achieved similar clinical responses (e.g., 50% of patients treated with beclomethasone achieved an improvement in FEV<sub>1</sub> of approximately 11% or more over baseline while approximately 42% of patients treated with montelukast achieved the same response).</p><p>In an 8-week study in paediatric patients 6 to 14 years of age, montelukast 5 mg once daily, compared with placebo, significantly improved respiratory function (FEV<sub>1</sub> 8.71% vs 4.16% change from baseline; AM PEFR 27.9 L/min vs 17.8 L/min change from baseline) and decreased &ldquo;as-needed&rdquo; &beta;-agonist use (- 11.7% vs +8.2% change from baseline).</p><p>In a 12-month study comparing the efficacy of montelukast to inhaled fluticasone on asthma control in paediatric patients 6 to 14 years of age with mild persistent asthma, montelukast was non-inferior to fluticasone in increasing the percentage of asthma rescue-free days (RFDs), the primary endpoint.</p><p>Averaged over the 12-month treatment period, the percentage of asthma RFDs increased from 61.6 to</p><p>84.0 in the montelukast group and from 60.9 to 86.7 in the fluticasone group. The between group difference in LS mean increase in the percentage of asthma RFDs was statistically significant (-2.8 with a 95% CI of -4.7, -0.9), but within the limit pre-defined to be clinically not inferior. Both montelukast and fluticasone also improved asthma control on secondary variables assessed over the 12 month treatment period:</p><p>FEV<sub>1</sub> increased from 1.83 L to 2.09 L in the montelukast group and from 1.85 L to 2.14 L in the fluticasone group. The between-group difference in LS mean increase in FEV<sub>1</sub> was -0.02 L with a 95% CI of -0.06, 0.02. The mean increase from baseline in % predicted FEV<sub>1</sub> was 0.6% in the montelukast treatment group, and 2.7% in the fluticasone treatment group. The difference in LS means for the change from baseline in the % predicted FEV<sub>1</sub> was significant: -2.2% with a 95% CI of -3.6, -0.7.</p><p>The percentage of days with &beta;-agonist use decreased from 38.0 to 15.4 in the montelukast group, and from 38.5 to 12.8 in the fluticasone group. The between group difference in LS means for the percentage of days with &beta;-agonist use was significant: 2.7 with a 95% CI of 0.9, 4.5.</p><p>The percentage of patients with an asthma attack (an asthma attack being defined as a period of worsening asthma that required treatment with oral steroids, an unscheduled visit to the doctor&#39;s office, an emergency room visit, or hospitalisation) was 32.2 in the montelukast group and 25.6 in the fluticasone group; the odds ratio (95% CI) being significant: equal to 1.38 (1.04, 1.84).</p><p>The percentage of patients with systemic (mainly oral) corticosteroid use during the study period was 17.8% in the montelukast group and 10.5% in the fluticasone group. The between group difference in LS means was significant: 7.3% with a 95% CI of 2.9; 11.7.</p><p>Significant reduction of exercise-induced bronchoconstriction (EIB) was demonstrated in a 12-week study in adults (maximal fall in FEV<sub>1</sub> 22.33% for montelukast vs 32.40% for placebo; time to recovery to within 5% of baseline FEV<sub>1</sub> 44.22 min vs 60.64 min). This effect was consistent throughout the 12-week study period. Reduction in EIB was also demonstrated in a short term study in paediatric patients (maximal fall in FEV<sub>1</sub> 18.27% vs 26.11%; time to recovery to within 5% of baseline FEV<sub>1</sub> 17.76 min vs</p><p>27.98 min). The effect in both studies was demonstrated at the end of the once-daily dosing interval.</p><p>In aspirin-sensitive asthmatic patients receiving concomitant inhaled and/or oral corticosteroids, treatment with montelukast, compared with placebo, resulted in significant improvement in asthma control</p><p>(FEV<sub>1</sub> 8.55% vs -1.74% change from baseline and decrease in total &beta;-agonist use -27.78% vs 2.09% change from baseline).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Montelukast is rapidly absorbed following oral administration. For the 10 mg film-coated tablet, the mean peak plasma concentration (C<sub>max</sub>) is achieved three hours (T<sub>max</sub>) after administration in adults in the fasted state. The mean oral bioavailability is 64%. The oral bioavailability and C<sub>max</sub> are not influenced by a standard meal. Safety and efficacy were demonstrated in clinical trials where the 10 mg film-coated tablet was administered without regard to the timing of food ingestion.</p><p>For the 5 mg chewable tablet, the C<sub>max</sub> is achieved in two hours after administration in adults in the fasted state. The mean oral bioavailability is 73% and is decreased to 63% by a standard meal.</p><p><u>Distribution</u></p><p>Montelukast is more than 99% bound to plasma proteins. The steady-state volume of distribution of montelukast averages 8-11 litres. Studies in rats with radiolabeled montelukast indicate minimal distribution across the blood-brain barrier. In addition, concentrations of radiolabelled material at 24 hours post-dose were minimal in all other tissues.</p><p><u>Biotransformation</u></p><p>Montelukast is extensively metabolised. In studies with therapeutic doses, plasma concentrations of metabolites of montelukast are undetectable at steady state in adults and children.</p><p>Cytochrome P450 2C8 is the major enzyme in the metabolism of montelukast. Additionally CYP 3A4, and 2C9 may have a minor contribution, although itraconazole, an inhibitor of CYP 3A4, was shown not to change pharmacokinetic variables of montelukast in healthy subjects that received 10 mg montelukast daily. Based on <em>in vitro </em>results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6. The contribution of metabolites to the therapeutic effect of montelukast is minimal.</p><p><u>Elimination</u></p><p>The plasma clearance of montelukast averages 45 ml/min in healthy adults. Following an oral dose of radiolabelled montelukast, 86% of the radioactivity was recovered in 5-day faecal collections and &lt;0.2%</p><p>was recovered in urine. Coupled with estimates of montelukast oral bioavailability, this indicates that montelukast and its metabolites are excreted almost exclusively via the bile.</p><p><u>Characteristics in Patients</u></p><p>No dosage adjustment is necessary for the elderly or mild to moderate hepatic insufficiency. Studies in patients with renal impairment have not been undertaken. Because montelukast and its metabolites are eliminated by the biliary route, no dose adjustment is anticipated to be necessary in patients with renal impairment. There are no data on the pharmacokinetics of montelukast in patients with severe hepatic insufficiency (Child-Pugh score &gt;9).</p><p>With high doses of montelukast (20- and 60-fold the recommended adult dose), a decrease in plasma theophylline concentration was observed. This effect was not seen at the recommended dose of 10 mg once daily.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In animal toxicity studies, minor serum biochemical alterations in ALT, glucose, phosphorus and triglycerides were observed which were transient in nature. The signs of toxicity in animals were increased excretion of saliva, gastro-intestinal symptoms, loose stools and ion imbalance. These occurred at dosages which provided &gt;17-fold the systemic exposure seen at the clinical dosage. In monkeys, the adverse effects appeared at doses from 150 mg/kg/day (&gt;232-fold the systemic exposure seen at the clinical dose). In animal studies, montelukast did not affect fertility or reproductive performance at systemic exposure exceeding the clinical systemic exposure by greater than 24-fold. A slight decrease in pup body weight was noted in the female fertility study in rats at 200 mg/kg/day (&gt;69-fold the clinical systemic exposure). In studies in rabbits, a higher incidence of incomplete ossification, compared with concurrent control animals, was seen at systemic exposure &gt;24-fold the clinical systemic exposure seen at the clinical dose. No abnormalities were seen in rats. Montelukast has been shown to cross the placental barrier and is excreted in breast milk of animals.</p><p>No deaths occurred following a single oral administration of montelukast sodium at doses up to 5,000 mg/kg in mice and rats (15,000 mg/m<sup>2</sup> and 30,000 mg/m<sup>2</sup> in mice and rats, respectively), the maximum</p><p>dose tested. This dose is equivalent to 25,000 times the recommended daily adult human dose (based on an adult patient weight of 50 kg).</p><p>Montelukast was determined not to be phototoxic in mice for UVA, UVB or visible light spectra at doses up to 500 mg/kg/day (approximately &gt;200-fold based on systemic exposure).</p><p>Montelukast was neither mutagenic in <em>in vitro </em>and <em>in vivo </em>tests nor tumorigenic in rodent species.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol Powder</p><p>Mannitol DC</p><p>Microcrystalline cellulose 102</p><p>Hydroxypropyl cellulose EXF</p><p>Red Iron oxide</p><p>Croscarmellose sodium</p><p>Bubble gum flavor</p><p>Colloidal silicon dioxide</p><p>Magnesium stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in the original package in order to protect from light and moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Blisters in packages of 28 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Alrai Pharmaceutical Industries Co. (L.L.C)
Al Wadi - 2, Almu'tasem Bellah Al Fatemy Street P.O.Box : 9224
Jeddah – 21413
Kingdom of Saudi Arabia
Tel	: +966 12 2888949
Fax	: +96612 2889014
E-mail : Info@alraipharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                09 / 2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>